XTX Topco Ltd Has $241,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)

XTX Topco Ltd lowered its position in Zymeworks Inc. (NYSE:ZYME) by 40.0% during the first quarter, according to its most recent filing with the SEC. The firm owned 20,205 shares of the company’s stock after selling 13,497 shares during the period. XTX Topco Ltd’s holdings in Zymeworks were worth $241,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ZYME. Picton Mahoney Asset Management lifted its stake in shares of Zymeworks by 0.7% in the 1st quarter. Picton Mahoney Asset Management now owns 208,029 shares of the company’s stock valued at $2,477,000 after purchasing an additional 1,460 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Zymeworks by 25.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,531 shares of the company’s stock valued at $292,000 after buying an additional 4,920 shares during the period. CWM LLC lifted its stake in Zymeworks by 1,091.2% in the first quarter. CWM LLC now owns 2,299 shares of the company’s stock valued at $27,000 after buying an additional 2,106 shares during the period. Duncan Williams Asset Management LLC acquired a new position in shares of Zymeworks during the 1st quarter valued at $263,000. Finally, Janney Montgomery Scott LLC lifted its position in shares of Zymeworks by 12.7% during the 1st quarter. Janney Montgomery Scott LLC now owns 11,567 shares of the company’s stock valued at $138,000 after acquiring an additional 1,300 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Zymeworks Price Performance

ZYME opened at $13.02 on Wednesday. The firm has a market capitalization of $907.27 million, a PE ratio of -8.68 and a beta of 1.26. Zymeworks Inc. has a fifty-two week low of $9.03 and a fifty-two week high of $17.70. The company’s 50-day moving average is $12.95 and its 200 day moving average is $12.66.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.52) by $0.55. The firm had revenue of $48.73 million during the quarter, compared to the consensus estimate of $17.18 million. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The company’s quarterly revenue was up 153.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.49) earnings per share. As a group, analysts expect that Zymeworks Inc. will post -1.39 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on ZYME. TD Securities assumed coverage on shares of Zymeworks in a research report on Tuesday, May 20th. They set a “buy” rating on the stock. TD Cowen assumed coverage on Zymeworks in a research note on Tuesday, May 20th. They set a “buy” rating on the stock. Citigroup upped their price target on Zymeworks from $19.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $13.00 price target on shares of Zymeworks in a research note on Thursday, July 3rd. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.43.

Insider Activity at Zymeworks

In other news, Director Ecor1 Capital, Llc bought 5,919 shares of the stock in a transaction dated Monday, May 19th. The stock was bought at an average price of $11.78 per share, for a total transaction of $69,725.82. Following the completion of the acquisition, the director directly owned 17,883,908 shares in the company, valued at approximately $210,672,436.24. This trade represents a 0.03% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.92% of the stock is currently owned by corporate insiders.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.